Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris 11:37:40 2024-07-11 am EDT After market 03:34:03 pm
93.81 EUR +0.28% Intraday chart for Sanofi 94.04 +0.25%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices RE
Sanofi Ships U.S. Influenza Vaccines for the 2024/25 Season CI
SANOFI : Receives a Sell rating from Deutsche Bank ZD
SANOFI : UBS reiterates its buy recommendation CF
Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday MT
SANOFI : UBS maintains a Buy rating ZD
Kymera Reports Expansion of KT-474 Trials; Shares Rise After-Hours MT
Kymera Therapeutics, Inc. Announces Expansion of KT-474 HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy CI
SANOFI : Jefferies maintains a Buy rating ZD
SANOFI : Stifel slightly raises its target on the stock CF
That's not so bad, is it? Our Logo
Sector Update: Health Care Stocks Steady Premarket Friday MT
Sector Update: Health Care MT
GlaxoSmithkline Pharmaceuticals Limited Announces Change in Management CI
Sanofi's Consumer Health Unit Receives Interest from French State MT
Bpifrance eyes investment in Sanofi's consumer health business RE
Bain Capital, Cinven, Others Said Mulling Bids for Sanofi's Consumer Health Unit MT
Bain, Cinven Explore Joint Bid for Sanofi's Consumer Unit, Bloomberg Reports DJ
Paul Hudson, CEO of Sanofi: AI to improve organisational efficiency MT
Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division MT
Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division MT
Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division, Bloomberg Reports MT
SANOFI : Berenberg reiterates its Buy rating ZD
SANOFI : JP Morgan remains Neutral ZD
Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits MT
Chart Sanofi
More charts
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
93.55 EUR
Average target price
108.8 EUR
Spread / Average Target
+16.32%
Consensus
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. Sanofi Appoints Nestlé CFO to Same Role